Researchers at Roswell Park Cancer Institute (RPCI) have identified a mechanism of breast cancer cells that leads to chemotherapy resistance in inflammatory breast cancer. These preclinical findings, published online ahead of print in the International Journal of Oncology, provide evidence for a potential therapeutic approach that will restore sensitivity to chemotherapy and improve treatment of inflammatory breast cancer tumors.

“This study forms the basis for future research in patients with breast cancer and offers hope for targeted therapy for patients with aggressive triple-negative inflammatory breast cancer,” said lead researcher Mateusz Opyrchal, MD, PhD, Assistant Professor of Oncology at RPCI.

READ FULL ARTICLE Curated publisher From Medical Express